Plus   Neg

Opexa Therapeutics Inc. (OPXA) Leaped Higher After Merck Agreement

Opexa Therapeutics Inc. (OPXA) announced Tuesday that it entered into an agreement with Merck Serono, for the development and commercialization of Tcelna, a potential first-in-class personalized T-cell therapy for patients with multiple sclerosis.

Opexa Therapeutics gapped open sharply higher Tuesday, but then declined until around midday. The stock ended the day higher by 1.94 at $3.15 on the highest volume of the year. Opexa Therapeutics leaped to a 3 1/2 month high and re-crossed its 50 and 200-day moving averages.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT